Down-regulation of MRPS23 inhibits rat breast cancer proliferation and metastasis
Open Access
- 15 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (42), 71772-71781
- https://doi.org/10.18632/oncotarget.17888
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Yan Gao1, *, Fuyan Li1, *, Hong Zhou1, Yi Yang1, Ruimin Wu1, Yijia Chen1, Wei Li1, Yang Li1, Xueqin Xu1, Changbin Ke1 and Zhijun Pei1 1 Department of PET Center and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of medicine, Hubei, China *These authors contributed equally to this work Correspondence to: Zhijun Pei, email: pzjun1980@yeah.net Changbin Ke, email: changbinke@gmail.com Keywords: MRPS23, breast cancer, metastasis, p53, p21 WAF1/CIP1 Received: October 31, 2016 Accepted: April 28, 2017 Published: May 15, 2017 ABSTRACT Mitochondrial ribosomal protein S23 (MRPS23) has been shown to be involved in breast cancer cell proliferation and metastatic phenotypes of cervical cancer. Here we investigated its biological features in breast cancer for the first time. It demonstrated that knockdown of MRPS23 reduced breast cancer cell proliferation and induced apoptosis in vitro. Besides, shRNA targeting MRPS23 (shMRPS23) inhibited tumour proliferation and metastasis by blocking tumor angiogenesis in breast cancer xenograft rat model. Small animal positron emission tomography/computed tomography (PET/CT) with 2’-deoxy-2’-[18F] fluoro-D-glucose (FDG) was performed at four weeks after tumour cell injection. We found that FDG maximum standardized uptake value (SUVmax) significantly decreased by 31 ± 3% in the shMRPS23-treated group. But this change was not independent of metabolic tumour size. In addition, we also found that shMRPS23 could significantly suppress breast cancer metastasis through inhibiting epithelial mesenchymal transition (EMT) phenotype. The epithelial marker E-cadherin was increased, whereas the metastasis associated gene vimentin was decreased. Mechanistically, shMRPS23-treated tumours failed to progress through p53 and p21WAF1/CIP1 activation, but not cytochrome c-mediated pathway. These findings suggest that MRPS23 is a potential therapeutic target for interference of breast cancer proliferation, angiogenesis and metastasis.Keywords
This publication has 43 references indexed in Scilit:
- Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancerBMC Cancer, 2013
- A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of AngiogenesisCancer Cell, 2013
- p53 Opens the Mitochondrial Permeability Transition Pore to Trigger NecrosisCell, 2012
- TATA-binding Protein (TBP)-like Protein Is Required for p53-dependent Transcriptional Activation of Upstream Promoter of p21Waf1/Cip1 GeneOnline Journal of Public Health Informatics, 2012
- Human ERAL1 is a mitochondrial RNA chaperone involved in the assembly of the 28S small mitochondrial ribosomal subunitBiochemical Journal, 2010
- Imaging bone metastases in breast cancer: techniques and recommendations for diagnosisThe Lancet Oncology, 2009
- Mitochondrial ribosomal protein S36 delays cell cycle progression in association with p53 modification and p21WAF1/CIP1 expressionJournal of Cellular Biochemistry, 2006
- Mitochondrial ribosomal protein L41 mediates serum starvation-induced cell-cycle arrest through an increase of p21WAF1/CIP1Biochemical and Biophysical Research Communications, 2005
- Mitochondrial Ribosomal Protein L41 Suppresses Cell Growth in Association with p53 and p27Kip1Molecular and Cellular Biology, 2005
- Identification of up-regulated genes in human uterine leiomyoma by suppression subtractive hybridizationCell Research, 2002